AA
ABBV icon

Antipodean Advisors’s AbbVie ABBV Stock Holding History

Antipodean Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-317,000
Closed -$21.3M – 26
2015
Q2 		$21.3M Buy
+317,000
New +$20.7M 2.2% 17

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Antipodean Advisors's ABBV Position: Q3 2015 in Review

Antipodean Advisors sold out of AbbVie (ABBV) in Q3 2015, closing a stake of 317,000 shares — an estimated $21.3M sold.

Antipodean Advisors first reported a position in ABBV in Q2 2015 and held it in 1 quarter. The position peaked at $21.3M in Q2 2015. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

  • Antipodean Advisors reported no remaining AbbVie position as of Q3 2015 after selling out during the quarter.
  • Antipodean Advisors sold 317,000 AbbVie shares in Q3 2015, an estimated $21.3M.
  • Antipodean Advisors first reported a position in AbbVie in Q2 2015 and held it in 1 quarter.
  • Antipodean Advisors's AbbVie position peaked at $21.3M in Q2 2015.
  • 1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Antipodean Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.